Browsing by Author "Uribe San Martín, Reinaldo"

Now showing 1 - 15 of 15
  • Thumbnail Image
    Item
    EEG findings and clinical prognostic factors associated with mortality in a prospective cohort of inpatients with COVID-19
    (2020) Skorin, I.; Carrillo, R.; Pérez, C. P.; Sánchez, N.; Parra, J.; Troncoso, P.; Uribe San Martín, Reinaldo
  • Thumbnail Image
    Item
    Frontoparietal connectivity correlates with working memory performance in multiple sclerosis
    (2020) Figueroa Vargas, Alejandra; Carcamo, Claudia; Henriquez Ch, Rodrigo; Zamorano, Francisco; Ciampi Diaz, Ethel Leslie; Uribe San Martín, Reinaldo; Vásquez, Macarena; Aboitiz, Francisco; Billeke, Pablo
    Working Memory (WM) impairment is the most common cognitive deficit of patients with Multiple Sclerosis (MS). However, evidence of its neurobiological mechanisms is scarce. Here we recorded electroencephalographic activity of twenty patients with relapsing-remitting MS and minimal cognitive deficit, and 20 healthy control (HC) subjects while they solved a WM task. In spite of similar performance, the HC group demonstrated both a correlation between temporoparietal theta activity and memory load, and a correlation between medial frontal theta activity and successful memory performances. MS patients did not show theses correlations leading significant differences between groups. Moreover, cortical connectivity analyses using granger causality and phase-amplitude coupling between theta and gamma revealed that HC group, but not MS group, presented a load-modulated progression of the frontal-to-parietal connectivity. This connectivity correlated with working memory capacity in MS groups. This early alterations in the oscillatory dynamics underlaying working memory could be useful for plan therapeutic interventions.
  • Thumbnail Image
    Item
    Multiple sclerosis and related disorders: Short report peripheral vascular events in a real-world cohort of multiple sclerosis patients using Fingolimod
    (2020) Pelayo, Carolina; Ciampi Díaz, Ethel Leslie; Uribe San Martín, Reinaldo; Soler León, Bernardita María; Reyes, Ana; Vergara, Elizabeth; Cárcamo Rodríguez, Claudia Andrea
    Background: Fingolimod is a high-efficacy disease-modifying therapy for multiple sclerosis (MS) and was the first oral treatment approved for the disease. Adverse events include bradyarrhythmia, hypertension, macular oedema and increased risk of infections, mainly due to its main mechanism of action, the non-selective modulation of sphingosine-1-phosphate receptor.", "Methods and Results: We report the baseline characteristics, effectiveness outcomes and adverse events of a prospective cohort of 177 patients with a median treatment duration of 24 months, in which four patients (2.3%) presented with otherwise non-provoked peripheral vascular events (PVE).", "Conclusions: Further studies are still needed to evaluate the frequency and severity of PVE in fingolimod patients.
  • Thumbnail Image
    Item
    Plasma urate in REM sleep behavior disorder
    (2013) Uribe San Martín, Reinaldo; Venegas Francke, Pablo; López Illanes, Felipe; Jones Gazmuri, Alex; Salazar Rivera, Julio; Godoy F., Jaime; Santín Martínez, Julia María; Juri Clavería, Carlos Andrés
  • Thumbnail Image
    Item
    Pregnancy outcomes in women with Multiple Sclerosis
    (2021) Soler León, Bernardita María; Ciampi, Ethel; Uribe San Martín, Reinaldo; Keller K.; Astudillo M.; Charaf V.; Reyes A.; Vergara E.; Cárcamo Rodríguez, Claudia Andrea
  • Thumbnail Image
    Item
    Prevalence of comorbidities in Multiple Sclerosis and impact on physical disability according to disease phenotypes
    (2020) Ciampi, Ethel; Uribe San Martín, Reinaldo; Soler León, Bernardita María; Molnar, Karolyn; Reyes Placencia, Diego Armando; Keller Matamala, Karina Pascale; Cárcamo Rodríguez, Claudia Andrea
    Background: Comorbidities are prevalent among Multiple Sclerosis (MS) patients. Few studies have characterized their prevalence and impact in Latin American populations.Objective: We aim to assess the prevalence of comorbidities and their impact on the risk of physical disability across different MS phenotypes.Methods: Cross-sectional multicenter study of patients under regular clinical care at the Programa de Esclerosis Múltiple UC and Hospital Dr. Sótero del Río in Chile. Prevalence of comorbidities was estimated from the retrospective assessment of electronic medical charts. Disease phenotypes were categorized into two groups: clinically isolated syndrome/relapsing-remitting (inflammatory group) and primary/secondary progressive MS patients (progressive group). A multivariable analysis using binary logistic regression for assessing the risk of EDSS ≥ 6.0 in each group was performed.Results: A total of 453 patients was included, 71% female, mean age at onset 31 years, mean disease duration 10 years, and median EDSS 2.0 (range 0–10). In the whole sample, most prevalent comorbidities were ever-smoking (42.2%), depression/anxiety (34.9%), thyroid disease (15.7%), hypertension (11.3%) and insulin resistance/type 2 diabetes mellitus (11.0%). When assessing the risk of EDSS ≥ 6, in the inflammatory group (N = 366), age at onset (OR 1.06, 95%CI(1.02–1.11), p = 0.008), disease duration (OR 1.06, 95%CI(1.00–1.12), p = 0.039) and epilepsy comorbidity (OR 5.36, 95%CI(1.33–21.5), p = 0.018) were associated with a higher risk of disability. In the progressive group (N = 87), disease duration was a risk factor (OR 1.08 95%CI(1.02–1.16), p = 0.014), while shorter diagnostic delay (OR 0.91 95%CI(0.85–0.99), p = 0.025) and insulin resistance/type 2 diabetes mellitus comorbidity were protective factors (OR 0.18 95%CI(0.04–0.83), p = 0.028), 72% of these patients were receiving metformin.Conclusions: Comorbidities are common across different MS disease phenotypes. Epilepsy seems particularly related with a higher risk of physical disability in relapsing-remitting patients, while the role of insulin resistance/type 2 diabetes mellitus or the impact of metformin use as a protective factor should be further studied. Prospective and larger studies are still needed in order to assess the real impact of comorbidities and their management in MS outcomes.
  • Thumbnail Image
    Item
    Prevalence of epilepsy in a cohort of patients with multiple sclerosis
    (2014) Uribe San Martín, Reinaldo; Ciampi, Ethel; Suárez Hernández, F.; Vasquez Torres, M.; Godoy F., Jaime; Cárcamo Rodríguez, Claudia Andrea
  • Thumbnail Image
    Item
    Refractory epilepsy associated with anti-ribosomal P antibodies successfully treated with topiramate
    (2020) Uribe San Martín, Reinaldo; Ciampi, Ethel; Cruz, Juan Pablo; Vásquez, M.; Cárcamo Rodríguez, Claudia Andrea
  • Thumbnail Image
    Item
    Relationship between Social Cognition and traditional cognitive impairment in Progressive Multiple Sclerosis and possible implicated neuroanatomical regions
    (2018) Ciampi, Ethel; Uribe San Martín, Reinaldo; Vásquez, M.; Ruiz-Tagle, A.; Labbé Atenas, Tomás; Cruz, J. P.; Lillo, P.; Slachevsky, A.; Reyesk, D.; Reyes, A.; Cárcamo Rodríguez, Claudia Andrea
  • Thumbnail Image
    Item
    Risk factors of early adverse drug reactions with phenytoin: A prospective inpatient cohort
    (2017) Uribe San Martín, Reinaldo; Ciampi, Ethel; Uslar, Wilhelm; Villagra, Silvana; Plaza Plaza, José Cristián; Godoy F., Jaime; Mellado T., Patricio
  • Thumbnail Image
    Item
    Secondary paroxysmal dyskinesia in multiple sclerosis: Clinical-radiological features and treatment. Case report of seven patients.
    (2017) Ciampi, Ethel; Uribe San Martín, Reinaldo; Godoy Santín, Jaime; Cruz, Juan Pablo; Cárcamo Rodríguez, Claudia Andrea; Juri Clavería, Carlos Andrés
  • Thumbnail Image
    Item
    Síndrome anti-GQ1b : Descripción de cuatro pacientes y revisión de la literatura
    (2013) Uribe San Martín, Reinaldo; Suárez, F.; Sandoval, Patricio; Mellado T., Patricio
  • Thumbnail Image
    Item
    Socioeconomic, health-care access and clinical determinants of disease severity in Multiple Sclerosis in Chile
    (2023) Ciampi Díaz, Ethel Leslie; Soler León, Bernardita María; Uribe San Martín, Reinaldo; Jurgensen Heinrich, Lukas; Guzmán, I.; Keller Matamala, Karina Pascale; Reyes C., Ana Belén; Bravo Grau, Sebastián Eduardo; Cruz, Juan Pablo; Cárcamo Rodríguez, Claudia Andrea
    Background: MS severity may be affected by genetic, patient-related, disease-related and environmental factors. Socioeconomic status, including income and healthcare access, amongst others, may also have a role in affecting diagnostic delay or therapy prescription. In Chile, two main healthcare systems exist, public-healthcare and private-healthcare, nonetheless universal care laws (e.g., access to High Efficacy Therapy-HET), including both systems, have been recently enacted for people with MS. Objective: To assess the role of Socioeconomic Conditions (SEC), clinical variables and public health policies on the impact of disease severity of MS patients in Chile. Methods: Multicentric, observational, cross-sectional study including patients from two reference centres (1 national reference centre from the private-health system and 1 regional reference centre from the public-health system). SEC and clinical variables included healthcare insurance (private or public), subclassification of health insurance according to monthly income, sex, age at onset, diagnostic delay, disease duration, diagnosis before HET law (as a proxy of HET delay), and current HET treatment. Progression Index (PI), EDSS ≥6.0 and Progressive MS diagnosis were used as outcome measures. Multivariable binary logistic regression was performed. Results: We included 604 patients (460 private-health, 144 public-health), 67% women, 100% white/mestizo, 88% RRMS, mean age 42±12 years, mean age at onset 32±11 years, mean disease duration 10±6 years, median diagnostic delay 0 (0–34) years, 86% currently receiving any DMT, 55% currently receiving HET, median EDSS at last visit of 2.0 (0–10), and median PI 0.17 (0–4.5). Lower monthly income was associated with higher EDSS and higher PI. In the multivariable analysis, public-healthcare (OR 10.2), being diagnosed before HET-law (OR 4.89), longer diagnostic delay (OR 1.26), and older age at onset (OR 1.05) were associated with a higher risk of PI>0.2, while current HET (OR 0.39) was a protective factor. Diagnosis before HET-law (OR 7.59), public-healthcare (OR 6.49), male sex (OR 2.56), longer disease duration (OR 1.2) and older age at onset (OR 1.1) were associated with a higher risk of Progressive MS. Public-healthcare (OR 5.54), longer disease duration (OR 1.14) and older age at onset (OR 1.08) were associated with a higher risk of EDSS ≥6.0 while current treatment with HET had a trend as being a protective factor (OR 0.44, p = 0.05). Conclusion: MS severity is impacted by non-modifiable factors such as sex and age at onset. Interventions focused on shortening diagnostic delay and encouraging early access to high-efficacy therapies, as well as initiatives that may reduce the disparities inherent to lower socioeconomic status, may improve outcomes in people with MS.
  • Thumbnail Image
    Item
    Stereo-EEG ictal/interictal patterns and underlying pathologies
    (2019) Di Giacomo, R.; Uribe San Martín, Reinaldo; Mai, R.; Francione, S.; Nobili, L.; Sartori, I.; Gozzo, F.; Pelliccia, V.; Onofrj, M.; Lo Russo, G.; De Curtis, M.; Tassi, L.
  • Thumbnail Image
    Item
    Th1 and Th17 Cells and Associated Cytokines Discriminate among Clinically Isolated Syndrome and Multiple Sclerosis Phenotypes
    (2017) Arellano, Gabriel; Acuña, Eric; Reyes, Lilian I.; Ottum, Payton A.; De Sarno, Patrizia; Villaroel, Luis; Ciampi, Ethel; Uribe San Martín, Reinaldo; Cárcamo Rodríguez, Claudia Andrea; Naves, Rodrigo